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Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of 
clonal plasma cells in the bone marrow. In normal plasma cell development, cells undergo 
programmed DNA breaks and translocations, a process necessary for generation of a 
wide repertoire of antigen-specific antibodies. This process also makes them vulnerable 
for the acquisition of chromosomal defects. Well-known examples of these aberrations, 
already seen at time of MM diagnosis, are hyperdiploidy or the translocations involving the 
immunoglobulin heavy chain. Over the recent years, however, novel aspects concerning 
genomic instability and its role in tumor development, disease progression and nascence 
of refractory disease were identified. As such, genomic instability is becoming a very 
relevant research topic with the potential identification of novel disease pathways. In this 
review, we aim to describe recent studies involving murine MM models focusing on the 
deregulation of processes implicated in genomic instability and their clinical impact. More 
specifically, we will discuss chromosomal instability, DNA damage and repair responses, 
development of drug resistance, and recent insights into the study of clonal hierarchy 
using different murine MM models. Lastly, we will discuss the importance and the use of 
murine MM models in the pre-clinical evaluation of promising novel therapeutic agents.
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INTRODUCTION
Multiple myeloma (MM) is a bone marrow malignancy defined by the presence of atypical 
clonal plasma cells in the bone marrow. These cells produce a monoclonal protein, also called 
M-component, which is a derivative of a normal immunoglobulin protein and can be detected 
using protein electrophoresis on serum and/or urine of the patient. Symptomatic MM disease 
is typically preceded by a precursor state termed monoclonal gammopathy of undetermined 
significance (MGUS) (Kyle et al., 2002). Here, an M-component can be detected but in absence 
of any end-organ damage. Smouldering MM (SMM) is the intermediate disease stage, positioned 
between MGUS and MM in the disease evolution. In SMM, end-organ damage is also absent 
but higher levels of tumor burden are seen alongside a higher risk of progression toward MM 
(Kyle et al., 2002; Rajkumar et al., 2014). MM accounts for around 1% of all cancers and 10% 
of all hematological malignancies in Western populations (Moreau et al., 2013; Rajkumar 
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et  al., 2014). The treatment of MM has made an enormous 
evolution the last few years with the development of the 
so-called novel agents. Introduction of these agents, including 
proteasome inhibitors (bortezomib, ixazomib, carfilzomib), 
immunomodulatory  agents (thalidomide, lenalidomide, and 
pomalidomide) together with consolidation using high-dose 
melphalan followed by autologous stem cell salvage in fit patients, 
has already led to an immense improvement of overall survival 
in MM patients. Additionally, introduction of monoclonal 
antibodies targeting CD38 or SLAMF7 (daratumumab and 
elotuzumab) or cellular therapy (CAR-T) will most likely further 
improve treatment-free remission and OS in the MM patient 
population (Rajkumar et al., 2014; D’Agostino et al., 2017; Zhao 
et al., 2018). Unfortunately, nearly all patients will eventually 
relapse and develop refractory disease, wherefore MM is still 
seen as an incurable disease.
One aspect of the development of relapsed and refractory 
MM is genomic instability, which is already present at the time 
of diagnosis and can ultimately lead to clonal evolution and 
drug resistance (Bolli et al., 2014; Lohr et al., 2014; Walker 
et  al., 2015). This aspect of the disease implicates the fact 
that the medical need for a more thorough understanding of 
genomic instability in MM disease alongside novel therapeutic 
options, countering these processes, remains high. Important 
tools to study these topics in MM are the different MM 
murine models, which enable researchers to mimic human 
MM disease as close as possible in a controlled manner. In 
this review, we aim to focus on the different types of murine 
MM models available, their genetic aspects within the scope 
of genomic instability and the different research fields where 
these mouse models have been implicated to further our 
understanding of genomic instability in MM, and in the end, 
improve the outcome of our patients.
DESCRIPTION OF MECHANISTIC 
INSIGHTS OF DIFFERENT MURINE 
MM MODELS
Up till now, different murine MM models have been reported 
and used in biomedical research, aiming to study the pathological 
basis of MM disease on the one hand and identification of 
possible novel agents on the other (Table 1). Up to date, four 
different approaches to establish murine MM models have 
been described, being models with spontaneous development 
of MM disease versus models using an induction, transgenic or 
xenograft approach (Radl et al., 1988; Carrasco et al., 2007; Chesi 
et al., 2008; Morito et al., 2011). As the mechanism of generation 
is inherently distinct between the different types of murine 
models, differences in genomic build and possible correlation 
with human MM disease are present. As such, the ideal murine 
MM model, spanning all aspects of disease biology and genetic 
build, unfortunately does not exist. Each system has specific 
strengths and weaknesses, which need to be evaluated in view of 
the scientific question in need of answering.
5TMM Murine Myeloma Models
The 5T murine MM models are well characterized spontaneous 
syngeneic immunocompetent MM models. The model is based 
on the observation by Radl et al. that a small proportion of older 
animals from the C57BL/KaLwRij inbred strain develop a benign 
monoclonal gammopathy comparable to the MGUS state in 
human patients (Radl et al., 1979; Radl et al., 1988; Garrett et al., 
1997). As such, these animals have the potential to develop MM 
or to a lesser degree other B-cell malignancies, such as B-cell 
non-Hodgkin lymphoma. The 5TMM models were established 
using serial transplantation of bone marrow and as such closely 
TABLE 1 | Schematic overview of murine models available for studying MM disease biology. Models are categorized according to genetic build.
Model category Murine MM model Primary features
Xenograft models NOD/SCID
NOD/SCID/IL2Rgamma
Injection of MM cells (primary patient samples of cell lines) IV or SC.
MM disease has pathogenic features of injected material. Requires transplant.
MIS(TK)TRG6 Humanized model based on knock in of human growth factor and cytokine encoding genes. Facilitates 
multi-lineage engraftment of human immune and hematopoietic stem cells
SCID-hu Implantation of human embryonic bone fragments that can be inoculated with
human MM cells, lesser used due to ethical issues.
SCID-rab Model derived from SCID-hu model, implementing rabbit bone fragments.




5TMM models Syngeneic model from different 5TMM strains which developed spontaneously in aged C57BL/KaLwRij 
mice. Requires transplantation of model for propagation. Extensively characterised genetically.
Immunocompetent 
transgenic models
Eµ-XBP1 Overexpression of XBP1 isoform involved in MM pathogenesis and government of unfolded/ER stress response.
Eµ-MAF Regulation of MAF oncogene by murine immunoglobulin enhancer.
Model for human t(14,16) MM disease.
VK*Myc Overexpression of Myc in the post-germinal B-cell compartment through AID hypermutation. Indolent 
disease phenotype. Aggressive phenotype can be generated via serial transplantation.





Local injection of mineral oil derivatives results in local induction of plasma cell tumor. More representative of 
plasmocytoma than MM disease. MOPC315.BM model can be transplanted to resemble systemic disease
Single gene KO models i.e., rrm2 -/- Mostly generated to study single gene function.
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resemble human disease as it has been shown that interaction 
with the bone marrow microenvironment is important in 
disease development, clonal selection, and genomic instability. 
When transplanted into syngeneic mice, recipients develop the 
presence of a monoclonal protein and osteolytic bone disease, 
inevitably leading to hind limb paralysis (Manning et al., 1992; 
Vanderkerken et al., 2000; Vanderkerken et al., 2003). The 
5T33MM and 5T2MM models are the most characterized and 
widely used models of the 5TMM series. From the 5T33MM 
model, two clonally related in vitro growing cell lines were 
derived which are stroma independent, being the 5T33vt and 
5TGM1 cells. These models represent a single MM clone. It is 
important that these models have an intact immune system, 
a feature that is an important advantage when compared with 
immunocompromised MM animal models. Over the years, these 
models have been used extensively to study the different aspects 
of MM pathobiology.
Transgenic Murine MM Models
Other widely used murine MM models are the transgenic 
models, which involve overexpression of known MM oncogenes 
under control of an immunoglobulin enhancer. Three different 
models have been reported up to date. The Eµ-XBP1s murine 
transgenic model involves overexpression of the XBP-1 spliced 
isoform, necessary for the government of the unfolded protein/
ER stress response and plasma cell development (Carrasco 
et  al., 2007). These mice have been shown to develop an 
MGUS/MM phenotype, and gene expression profiling revealed 
enriched activity of pathways involved in hyperproliferation, 
IL-6 activation alongside dysregulation of genes known to be 
driven by recurrent chromosomal translocations in human 
MM disease. The Eµ-MAF model adopts a similar approach 
and involves regulation of c-MAF by the immunoglobulin 
enhancer in the murine B-cell compartment (Morito et al., 
2011). As such, transgenic Eµ-MAF mice serve as a model for 
human MM disease harboring t(14;16), which is known to lead 
to an aggressive MM phenotype and shorter survival. Thorough 
insights in the genetic instability in this model are, however, 
absent. The Vk*MYC model is a third transgenic model, in which 
the MYC oncogene becomes overexpressed in the post-germinal 
B-cell compartment via AID-dependent somatic hypermutation 
(Chesi et al., 2008). This model has been shown to give rise to 
a murine MM phenotype similar to human MM disease with 
an indolent phenotype at onset of disease, as such following 
the natural history of MM disease in humans to a great degree 
(Chesi et al., 2008; Chesi et al., 2012). An aggressive phenotype 
can, however, be generated using serial transplantation and can 
be a model for studying relapsed MM (Chesi et al., 2012). This 
model has already been extensively used for research into the 
pathogenesis and pre-clinical drug development (Chesi et al., 
2012; Matthews et al., 2013). A final transgenic murine MM 
model, which also focuses on overexpression of MYC oncogene 
is the Myc/Bcl-XL model (Cheung et al., 2004). This model 
was generated by creating a double-transgenic Myc/Bcl-XL 
mouse strain shown to develop plasma cell tumors with an 
average onset of 135 days at 100% tumor penetrance. The mice 
developed a monoclonal protein and displayed infiltration of the 
bone marrow by plasma cells.
Xenograft Murine MM Models
Xenograft models are immune incompetent murine MM models 
and are based on the engraftment of primary human MM 
cells or MM cell lines in immune compromised mice, such as 
severe combined immunodeficient (SCID), nude or non-obese 
diabetic (NOD)/SCID or NOD/SCID/IL2Rgamma mice. This 
model can be used to generate systemic or local disease through 
intravenous (IV) or local injection of MM cells, respectively. 
This approach has the advantage that it enables the study of 
homing of MM cells and to test novel therapeutic compounds 
in human MM cells in vivo (Mitsiades et al., 2003). Currently, 
several xenograft murine MM models exist, generated using 
the IV injection of primary patient samples or human MM cell 
lines, such as OPM2, JJN3, MM.1S, XG1, KMM-1, and RPMI-
8266 (Paton‐Hough et al., 2015). A relative drawback of these 
models is, however, the fact that the majority of human MM 
cell lines are primarily derived from primary human plasma cell 
leukemia samples which lack dependency on the bone marrow 
microenvironment. As such, human MM cell lines could be 
less representative of the more indolent course of a significant 
proportion of MM disease. Nevertheless, thorough genetic 
characterization of human MM cell lines has shown that MM 
cell lines cover the spectrum of molecular heterogeneity seen in 
patients, validating them as important tools for studying MM 
(Moreaux et al., 2011). Using primary patient samples alleviates 
this aspect but has implications on experimental setup due to 
patient variability. Recently, the MIS(KI)TRG6 murine MM model 
has been reported as a possible mouse model to study human 
cells in mice more easily. The model was generated by human 
IL-6 knock-in modification of MIS(KI)TRG mice, which were 
established by knocking in genes encoding human M-CSF, IL-3, 
GM-CSF, TPO, and SIRPα into the respective murine loci in 
immunodeficient Rag2-/- IL2Rgamma -/- mice. MIS(KI)TRG mice 
were shown to overcome the lack of inter-species cross-reactivity 
of these cytokines and growth factors to facilitate multi-lineage 
engraftment of human immune and hematopoietic stem cells 
(Rongvaux et al., 2014; Das et al., 2017). Subsequent knock-in 
of human IL-6, an important growth factor for human MM 
cells, generated an immunodeficient mouse strain in which cells 
derived from patients with MM or precursor lesions could be 
xenografted successfully and subsequently used for biomedical 
research (Das et al., 2017). SCID-based xenograft models that are 
less widely used today include the SCID-hu model. This model 
involves the implantation of human fetal bone subcutaneously. 
Afterward, human MM cells, both cell lines or primary patient 
material, can be injected directly into the engrafted bone. These 
mice will develop a spectrum of human MM characteristics, 
including bone disease and the presence of a paraprotein in the 
serum (Urashima et al., 1997; Yaccoby et al., 1998; Tassone et al., 
2005). Although this model was characterized by a high level of 
tumor engraftment, important ethical issues concerning the use 
of human embryonic material led to the abandonment of this 
murine model. Derivatives of this model include the SCID-rab 
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model, in which rabbit bones are implanted in replacement of 
human embryonic bone chips, and the SCID-synth-hu model, 
implementing a 3D polymeric scaffold coated with human 
bone marrow stromal cells (Yata and Yaccoby, 2004; Calimeri 
et al., 2011). Both models have the benefit that they overcome 
the ethical issues raised with the original SCID-hu model and 
have been implemented to study local MM disease (Yaccoby 
et al., 2007; Pennisi et al., 2009; Calimeri et al., 2011). Due to 
the nature of the bone material used, results cannot be readily 
extrapolated to human disease. Nowadays, the previously 
discussed MIS(KI)TRG6 model can, however, act as a full-fledged 
replacement of the SCID-hu model, due to the specific genetic 
build (Das et al., 2017).
Induced and Single Gene Knockout 
MM Models
Induced syngeneic MM models are immunocompetent and have 
been developed by using injection of mineral oil derivatives, such 
as pristane (Potter and Boyce, 1962; Anderson and Potter, 1969). 
An important remark concerning these models is the fact that 
they resemble more a solitary plasmacytoma phenotype and not 
so much MM disease. One such an induced model, the MOPC315.
BM model, has been described to be transplanted successfully 
in syngeneic animals, leading to successful homing of cells to 
the bone marrow and the axial skeleton (Hofgaard et al., 2012). 
More rarely, single gene knock-out mouse models are reported to 
develop plasma cell malignancies (Chang et al., 2013).
MOLECULAR AND GENETIC 
CHARACTERIZATION OF MM MURINE 
MODELS, FOCUSING ON GENOMIC 
INSTABILITY
Characterization of the different murine MM models must 
be approached in view of the mode of construction. As 
such, transgenic murine models are generally driven by the 
involved transgene, whereas xenograft models are dependent 
on the genetic build of the injected MM cells. Extensive 
characterization into the epigenetic deregulation and/or the 
presence of chromosomal instability in the different models is 
as such present in variable degree.
In the 5TMM models, our group recently performed an 
extensive genetic analysis using next-generation sequencing to 
evaluate copy number alterations (CNA) and the mutational 
spectrum (Maes et al., 2018). Analysis revealed that the 5T2MM 
cells contained focal amplifications involving oncogenes, such 
as Kras, Nras, Map2k2, and Pik3ca. The 5TGM1 and 5T33vv 
models also had focal Kras and Akt1 amplifications, respectively. 
These genes belong to the Ras/MapK and PI3K/Akt pathways, 
known to be involved in genomic instability. Additionally, several 
of the identified CNAs encompass genes involved in the Fanconi 
Anemia DNA-repair pathway. Strikingly, a deletion of the tumor 
suppressor, Brca2, involved in homologous recombination, was 
seen in all the 5TMM models. We also described an overlap of 
66.4% of genes affected by CNAs in gain of 1q in patients and 
genes affected by CNA in the 5T2 models. A more detailed 
analysis revealed an overlap of genes (Cks1b, ILf2, Adar, Arnt) 
described to be drivers of the poor prognostic features of gain(1q), 
which could be helpful to further explore why gain(1q), a known 
marker of high-risk disease, leads to a decrease in overall survival 
in myeloma patients (Shah et al., 2016). Similarly, a remarkable 
overlap of 69.9% of genes involved in del(13q) in patients and 
genes with CNAs in the 5T33 and 5TGM1 models was observed. 
A more detailed analysis confirmed the loss of important tumor 
suppressor genes including Rb1, Ebpl, and Rnaseh2. Interestingly, 
regions on chromosome 5 were commonly deleted in all 5TMM 
models and encompass Brca2, Flt3, Fgfr2, and Whsc1. Recently, 
a similar observation was reported in the Vk*MYC model using 
single-cell chromosomal copy number analysis. Copy number 
analysis showed that a loss of chromosome 5 was observed in 
the majority of MM cells from tumor bearing mice, where this 
was not observed in the normal plasma cell compartment. 
These observations, present both in the 5TMM and the Vk*Myc 
MM models, could suggest that CNAs of chromosome 5 are an 
early and highly prevalent event in murine MM pathobiology 
(Croucher et al., 2018) and show that genomic instability is an 
inherent trait of these murine MM models. These observations 
validate their potential use for exploring involved pathways in 
MM, especially since many of the observed genetic aberrations are 
known to be linked with poor prognosis in human MM disease 
(Manier et al., 2017). With respect to the mutational spectrum 
observed in the 5TMM models, the amount of non-synonymous 
mutations exceeds the amounts found in MM patients, indicating 
that the 5TMM models are more advanced stages of MM disease. 
Nevertheless, it is clear that the mutated genes are implicated in 
several key pathways known to be deregulated in MM. These 
include PI3K/Akt, growth factor-related signaling, cell cycle 
and DNA repair, and extracellular matrix organization. Genes 
with mutations that overlap with genes mutated in MM patients 
include homozygous deletion in Rb1 (5T2) and homozygous 
loss-of-function mutation in Trp53 (5T33, 5TGM1).
SPECIFIC TOPICS STRESSING 
IMPORTANCE OF MURINE MODELS 
IN MM
Murine MM models are, due to the significant genetic 
overlap with human disease, ideal models for studying 
MM pathogenesis and potential novel therapies. Moreover, 
they prove to be of use to study the concepts of epigenetic 
deregulation, DNA damage, chromosomal instability, and the 
subsequent processes of clonal selection and the development 
of drug resistance.
Use of Murine MM Models in the Study  
of Chromosomal Instability
Chromosomal instability (CIN) is a characteristic of cancer cells, 
not solely limited to B-cell malignancies. It can lead to numerical 
imbalances and has been described as an early event in MM 
disease with gain 1q and del 17p being the most well-known 
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examples. Moreover, CIN has been shown to influence survival 
in MM patients (Carter et al., 2006; Zhou et al., 2013).
Recently, the role of miR-137 in MM, located on the 
frequently deleted chromosomal locus 1p22 in MM disease, 
was studied using a murine xenograft model (Yang et al., 2015; 
Qin et al., 2016). They showed the presence of a significant 
inhibition of tumor formation without overt toxicity, alongside 
a significant and positive effect on overall survival. Subsequent 
analysis of tumor tissues revealed a significant effect on apoptosis 
with a decrease in MCL-1 and increase in BAD and PARP 
upon miR-137 overexpression. In a follow-up study, they were 
subsequently also able to, using a similar xenograft approach, 
investigate the epigenetic regulation or miR-137 and report 
effects of miR-137 therapy on CIN in MM. More specifically, 
the use of a murine MM model enabled them to evaluate the 
in vivo effects of miR-137 overexpression upon bortezomib 
treatment, showing smaller tumor volumes and an increased 
sensitivity to treatment due to downregulation of the AURKA/
p53/ATM/Chk2 pathway involved in apoptosis and CIN. These 
observations were corroborated by Shuaishuai et al. (2017) 
who used a similar xenograft approach to show that AURKA is 
involved in chromosomal instability and drug resistance through 
the DNA damage response Atr-Chk1-gammaH2AX pathway. 
Downregulation of AURKA promoted apoptosis and alleviated 
drug resistance. As mounting evidence shows that AURKA plays 
a role in (early) relapse of MM and drug resistance, inhibition 
of the AURKA pathway, using miRNA-137 modulation or 
direct inhibition, could prove an interesting therapeutic strategy 
targeting genomic instability.
Another implementation of murine models for expanding 
our insights into CIN was provided by Chang et al. (2013). They 
created a Rrm2b+/− knockout model (C57BL/6J background) and 
observed that these mice displayed higher levels of IL-6 when 
compared to wild-type littermates. Whereas Rrm2b-/- mice 
displayed a lethal phenotype by 7 weeks of age, heterozygous 
knockout mice showed persistent high levels of IL-6 and 
began developing infiltration of a CD138+/kappa+ plasma cell 
population in the bone marrow and splenic compartments, 
suggestive for the development of a plasma cell dyscrasia. 
Subsequent molecular analysis revealed that loss of Rrm2b 
function led to DNA damage through depletion of dNTP pools 
and activation of NF-KB and STAT3 signaling with persistent 
IL-6 secretion. Chromosomal analysis revealed the presence of 
marked chromosomal aberrations in Rrm2b+/− mice.
Other CIN genes that have been implicated in MM and 
are good examples of showing the contribution of murine 
MM models to the field are NEK2 and TRIP13. NEK2 was 
primarily identified as a CIN gene of interest by performing an 
intersection analysis of differentially expressed genes between 
paired MM patient samples from diagnosis and after induction 
chemotherapy on the one hand and paired MM patient samples 
from time of diagnosis and at early relapse (Zhou et al., 2013). 
A total of 56 common genes were identified of which 10 
genes (TOP2A, CDC20, TRIP13, NEK2, AURKA, RRM2, 
CCNB1, KIF4A, CEP55, and PBK) had a significant impact on 
survival and belonged to the CIN signature as reported in the 
literature (Carter et al., 2006; Zhou et al., 2013). NEK2 is a cell 
cycle-regulated protein kinase important for regulating correct 
centrosome separation during the G2 phase, and it also plays a 
role in activation of the G2 checkpoint (Fletcher et al., 2004). 
In vivo evaluation of NEK2 inhibition was evaluated by using 
a NOD-rag/null gamma xenograft model. Mice were injected 
with ARP1 cells transfected with a shRNA targeting NEK2 
or an empty vector. Mice bearing NEK2 downregulated-MM 
tumors displayed a marked inhibition of tumor growth when 
compared with control mice. Also, NEK2 downregulation in 
the bortezomib-resistant APR1-DR MM cell line resulted in a 
re-sensitization of these cells to bortezomib in vivo. A second 
CIN gene that has been validated in MM using murine models is 
the AAA-ATPase TRIP13, a key regulator of the spindle assembly 
checkpoint and chromosome structure (Tipton et al., 2012; Ye 
et al., 2015). Its importance in MM is also further stressed by 
the fact that it has been identified as part of the 70-gene high 
risk model of MM, which is linked with a dismal prognosis 
(Shaughnessy et al., 2007; Heuck et al., 2014). Tao et al. showed 
the functional importance of TRIP13 in MM pathogenesis using 
a NOD-RAG/null xenograft model. Mice were injected with 
OCI-MY5 cells transduced with TRIP13-shRNA or scrambled 
vectors and TRIP13 knockdown mice clearly showed less tumor 
burden compared to controls. As TRIP13 is associated with high-
risk disease, chromosomal instability, and drug resistance, its use 
as a biomarker of high-risk disease on the one hand and its use 
as a potential therapeutic target need to be explored in the future 
(Tao et al., 2017).
Drug Resistance, Risk Stratification,  
and Drug Development
Despite the availability of many novel agents, MM still remains 
an incurable disease due to the development of drug resistance 
and, ultimately, the development of refractory disease. It has 
been recently shown that the development of MM is not solely 
due to abnormalities of the plasma cells but also due to changes 
in the bone marrow microenvironment (Bianchi and Munshi, 
2015). The MM cells interact with cells of the bone marrow 
microenvironment through cell surface molecules and as such 
initiate signaling pathways influencing drug-induced apoptosis 
and MM cell survival. Also, the relative hypoxic state of the 
bone marrow microenvironment has been shown to influence 
MM cell survival and resistance to therapies. Identification of 
pathways involved in modulating drug resistance is therefore 
important, because this could lead to identification of possible 
novel treatment strategies. As there is an interplay between the 
MM cells and the bone marrow stroma, evaluation of potential 
new drugs in murine models adds an extra layer of evidence 
that the observed effects of the compound studied are not 
abrogated by the presence of MM–BM interactions and that 
the compounds under study have an acceptable toxicity profile 
in vivo, a prerequisite for further development. Many targets 
involved in MM drug resistance and the role of the bone marrow 
environment have already been identified. Here, selected certain 
targets can lead to novel therapeutic insights or the development 
of novel compounds and for which murine models have been 
extensively used.
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A gene of interest concerning this topic is FOXM1, coding 
for the forkhead box M1 transcription factor. It has been 
shown that overexpression of FOXM1 is upregulated in high-
risk MM and is correlated with shorter overall survival (Gu 
et al., 2015; Gu et al., 2018a). Gu et al. evaluated the role of 
FOXM1 in vivo data using a NOD/SCID/IL2Rgamma CAG 
xenograft model. Mice were inoculated with CAG cells with 
either normal or overexpressed FOXM1 and followed for 7 
days after which mice were treated with either bortezomib 
or drug vehicle. Tumor diameters were found to be larger in 
the control mice injected with cells overexpressing FOXM1 
as was comparable with earlier results. In mice treated with 
bortezomib however, FOXM1 overexpression resulted in 
a slight decrease in drug sensitivity (Gu et al., 2018b). This 
finding was compatible with earlier observations showing that 
downregulation of FOXM1 can enhance bortezomib-induced 
cell death in solid tumor cell lines (Pandit and Gartel, 2014).
Studying drug resistance using murine models is, however, 
also extremely interesting in the field of novel drug development. 
Recently, RRx-001 has been identified as a potential novel 
therapeutic agent in many malignancies. It is a dinitroazetidine 
derivative that induces immunomodulatory effects either 
through polarization of tumor-associated macrophages or 
via increased T-lymphocyte infiltration (Zhao et al., 2017). In 
vivo treatment with this compound using the human MM.1S 
xenograft mouse model decreased tumor burden and prolonged 
survival in treated animals, thus generating a proof of concept for 
clinical studies with RRx-001 (Das et al., 2016).
Mice models also lead to the introduction of the melphalan-
flufenamide dipeptide as a potential novel treatment in MM 
patients (Chauhan et al., 2013). Melphalan is an alkylating agent 
that is actively used in MM therapy. Unfortunately, treatment is 
associated with dose-limiting toxicity, as well as the development 
of resistance (Kumar et al., 2018). Melphalan-flufenamide, also 
called melflufen, has been shown to enhance the therapeutic 
potential of melphalan as its prodrug form allows the compound 
to accumulate intracellularly more rapidly and with higher 
concentrations. As such, Chauhan et al. evaluated the in vivo 
efficacy of melflufen using the human MM.1S xenograft mouse 
model. These experiments showed that melflufen was able to 
inhibit MM cell growth and prolong mice survival. Melflufen-
treated mice survived for a statistically significant longer time, 
identifying melflufen as a promising compound (Chauhan 
et al., 2013). As such, a current phase 3 trial is currently actively 
recruiting patients to evaluate the potential use of this drug as a 
treatment option.
As stated earlier, acquired drug resistance is a critical problem 
that every patient and healthcare provider has to face during MM 
treatment. Many second-generation novel agents have become 
available the last couple of years, but the need for other therapeutic 
approaches remains high. One of these approaches focuses on 
tackling drug resistance and spins off from the observation that 
many types of cancer cells use the transport of tumor-suppressive 
proteins from the nucleus to the cytoplasm. As such, tumor cells 
can render them functionally incapacitated and evade anti-cancer 
mechanisms via shuttling of key proteins, such as p53, Rb, or other 
cell cycle regulators (Turner et al., 2009; Turner et al., 2013). The 
implication of this mechanism in MM drug resistance was first 
described by Turner et al. in 2004, showing that MM cells actively 
export endogenous topoisomerase II alpha (TOP2A) toward the 
cytoplasm during MM cell growth, due to enhanced activity of 
the Exportin 1 protein (XPO1 or CRM1) (Turner et al., 2004). 
Subsequent inhibition of XPO1 function was shown to prevent 
export of TOP2A and sensitize drug-resistant MM cells to 
doxorubicin (Turner et al., 2016a). A similar effect was seen when 
treating primary samples from proteasome inhibitor-refractory 
MM patients with a combination of selinexor, a clinical XPO1 
inhibitor, and bortezomib or carfilzomib (Turner et al., 2016b). 
XPO1 inhibition was shown to be able to potentially overcome 
drug resistance in MM, thus warranting further exploration of 
XPO1 inhibitors both pre-clinical as clinical. In vivo use of XPO1 
inhibitors showed marked activity in a NOD/SCID mouse model 
in which both drug-resistant U266PSR and parental U266 cells 
were injected (Turner et al., 2016b). Mice were subsequently 
treated with doxorubicin and selinexor both in monotherapy 
and combination therapy. When compared with doxorubicin 
monotherapy, combination of doxorubicin with selinexor 
significantly reduced tumor burden and increased survival 
in mice injected with both parental and drug-resistant U266 
cells, showing that XPO-1 inhibition can overcome previously 
acquired drug resistance to a certain degree. Of interest, 60% and 
40% of combination-treated mice, challenged with parental or 
drug-resistant U266 cells, respectively, survived at termination 
of the study (timepoint of 4 months after injection), whereas all 
untreated control, doxorubicin, or selinexor monotherapy mice 
had to be euthanatized before the end of the experiment due to 
development of bulky disease. Toxicity, assessed by weight loss > 
10%, was acceptable and seen in 2% of treated mice. Due to these 
results both in vitro and in vivo, subsequent trials with selinexor 
were initiated in human patients both in monotherapy and in 
combination with standard of care agents with promising phase 
I/II results. As such, phase III results are eagerly awaited (Bahlis 
et al., 2018; Vogl et al., 2018). Of note, however, the toxicity 
profile in these trials was more elaborate when compared with 
murine studies.
DNA Damage and Repair Mechanisms and 
Their Involvement in Drug Development
Part of the mechanism contributing to overall genomic instability 
in MM can be explained through the deregulation of DNA 
damage and repair mechanisms. Recent studies state that the 
ongoing generation of DNA damage, coupled with deregulation 
of DNA damage repair, induces further generation of genomic 
changes (Shammas et al., 2009; Walters et al., 2011; Cottini et al., 
2015; Herrero et al., 2015). DNA damage repair mechanisms 
are necessary to limit the potential impact of insults to DNA 
integrity, such as double-stranded breaks (DSB), and maintain 
genomic stability and cellular viability (Ciccia and Elledge, 2010). 
DSBs can be caused by exogenous events, i.e., genotoxic stimuli, 
or endogenous events, such as replication stress. DSBs are mainly 
repaired via two distinct pathways, being non-homologous end 
joining repair (NHEJ) and homologous recombination (HR). 
NHEJ is based on direct ligation of the damaged DNA and is 
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involved in non–replication-associated DSBs. HR involves, on 
the other hand, processes that tackle DSBs generated during 
DNA replication (Brandsma and Gent, 2012). As replication 
stress and DNA damage have been described in subsets of MM 
patients and infer high-risk disease, further mechanistic insights 
are needed and could lead to development of novel compounds, 
treatment schemes, or drug repurposing (Cottini et al., 2015).
A remark that can be made concerning this topic is the fact 
that there are genes or pathways that are involved both in drug 
resistance and DNA repair mechanisms (Gourzones-Dmitriev 
et al., 2013). One of these, High Mobility Group 1 (HMGB1), 
is of potential interest as it is implicated in MM but also in 
many other malignant diseases. HMGB1 is a highly conserved 
gene. The protein acts as a nucleosome stabilizer and plays an 
important role in gene transcription, spatial arrangement, and 
DNA repair (Guo et al., 2018; Hong et al., 2019; Zhang et al., 
2019). To confirm HMGB1 as a potential target in vivo, Guo 
et al. inoculated NOD-SCID mice with RPMI8226 cells that were 
transfected with either control or HMGB1 shRNA. One week 
after injection, mice were randomized to receive dexamethasone 
treatment or placebo. These experiments showed that HGMB1 
knockdown mice had lower tumor burden after dexamethasone 
treatment. Although no reports concerning OS or toxicity were 
available, targeting HMGB1 from a therapeutic point of view 
certainly remains interesting (Guo et al., 2018).
Another possible example of exploiting the DNA damage repair 
in MM is the use of DNA methyltransferase inhibitors (DNMTi) 
and histone deacetylase inhibitors (HDACi). DNMTi, such as 
azacytidine and decitabine, have already been used in different 
hematological malignancies and one HDACi, panobinostat, has 
been investigated in clinical trials and is currently reimbursed in 
patients with RRMM when used in combination with bortezomib 
and dexamethasone (Jabbour et al., 2017; San-Miguel et al., 2017). 
We investigated the effect of decitabine treatment both in vitro and 
in vivo (Maes et al., 2014). We were able to show that exposure of 
MM cells to decitabine-induced cytotoxicity via DNA damage as 
higher levels of gamma-H2AX foci were seen alongside cell cycle 
arrest and caspase induction. Interestingly, combination of DNMTi 
with the HDACi quisinostat resulted in an enhanced cytotoxic 
effect. These in vitro findings were able to be reproduced in the 
5T33MM immunocompetent model. In a decitabine monotherapy 
experiment, mice were inoculated with 5T33MM cells and were 
treated with decitabine or placebo from day 1 of injection. Treated 
mice showed a significant, dose-dependent improvement of overall 
survival when compared with untreated mice. Proof-of-concept of 
combining DNMTi with HDACi was also reproducible in vivo, as 
mice treated with a combination of decitabine and quisinostat had 
a significant longer survival when compared to placebo or mice 
treated with these compounds in monotherapy.
The increased insights into the DNA damage and repair 
response lead to the development of EDO-S101. EDO-S101 
is a first-in-class alkylating HDACi fusion molecule that 
combines the DNA damaging effect of bendamustine, a nitrogen 
mustard derivative known to induce inter- and intra-strand 
DNA crosslinks, with the pan-HDACi vorinostat. The rationale 
behind the pre-clinical development of this fusion compound 
arises from the hypothesis that histone acetylation would 
induce a more opened chromatin structure that would be more 
susceptible to the alkylating moiety. In vitro treatment of different 
MM cell lines and primary patients’ samples indeed showed that 
EDO-S101 has potent anti-myeloma effects, independent of 
p53 status or melphalan resistance (López-Iglesias et al., 2017). 
In vivo activity and toxicity were subsequently evaluated in 
two independent murine MM models. CB17-SCID mice were 
SC injected with MM1.S cells to create an immune-deficient 
xenograft model and were subsequently treated with EDO-
S101 using two strategies. In a first approach, mice were treated 
from first day onward. Treated mice showed a slower tumor 
growth alongside a significant improvement in overall survival. 
Although a 10% to 20% loss of body weight was seen in treated 
mice, a spontaneous recovery was seen after the treatment. In 
a second study, CB17-SCID xenograft mice were treated after 
large plasmacytomas had been established. EDO-S101 prolonged 
OS when compared with placebo and reduced further tumor 
growth. Immunohistochemical analysis of tumor tissue showed 
an increase in gamma-H2AX foci. Results were subsequently 
validated in the Vk*MYC MM mouse model, although only a 
low number of mice were used. Interestingly, a significant OS 
improvement was also seen in the very aggressive and multidrug-
resistant Vk12653 model. These findings thus suggest that EDO-
S101 could be a possible compound for treating patients with 
RRMM, and a phase I study is currently actively investigating 
this compound in this setting (NCT02576496).
Homologous recombination (HR) is an important DNA repair 
mechanism. Another set of key enzymes in the maintenance of the 
genome are PARP1 and PARP2. These proteins are required for 
repair of single-start breaks and inhibition of PARP1/2 causes a 
collapse of the DNA replication fork and formation of DSBs. As 
such, a combinational inhibitory strategy could induce so called 
synthetic lethality. Possible targets of HR include the cyclin-
dependent kinases (CDK), which are upstream regulators of the 
HR pathway (Aylon et al., 2004). Alagpulinsa et al. (2016) adopted 
this approach and evaluated dinaciclib, a CDK inhibitor, in MM. 
They saw that exposure of different human MM cell lines abrogated 
HR repair and sensitized the cells to PARP inhibition using ABT-
888, a PARP1/2 inhibitor, thereby inducing synthetic lethality. 
In vivo experiments once again underline the added benefit of 
murine mouse models to validate in vitro findings. CB-17/SCID 
mice were injected with RPMI8226 cells and tumor size was 
evaluated approximately 14 days post-inoculation. Mice were 
randomized into four groups to receive either placebo, dinaciclib, 
ABT-888, or combination therapy. The obtained in vitro results 
could be reproduced in vivo as mice treated with both compounds 
had less tumor growth and a longer survival when compared 
with monotherapy with either compounds. Lastly, transcriptional 
analysis of excised tumor tissue was also able to show significant 
downregulation of Rad51 and Brca1 mRNA levels.
Study of Clonal Selection Using Murine 
MM Models
Over the last years, many novel insights concerning the presence 
and the importance of intratumor heterogeneity in cancer have 
become apparent. This biological concept is especially important 
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when looking at MM. Although the initiating event in MM are 
clonal in nature, additional driver lesions can occur in specific 
subpopulations, or subclones, of cells. This biological concept can 
thus facilitate subclonal selection during treatment, relapse, and 
eventually the development of RRMM. (Lohr et al., 2014; Rasche 
et al., 2017; Corre et al., 2018). Generally, three subtypes of clonal 
selection have been identified in MM, being i) the presence of a 
stable, unchanged clonal architecture, ii) linear clonal evolution, 
and iii) a branching evolution of the clonal architecture, which 
is most often seen at relapse and displays a higher degree of 
genomic instability (Bolli et al., 2014; Weinhold et al., 2016). 
Another layer of complexity is added due to an increasing body of 
data suggesting the presence of important fluctuations in clonal 
architecture during treatment and relapse (Keats et al., 2012).
Melchor et al. (2014) used a NOD/SCID xenograft model, 
using CD138+ cells from a patient with plasma cell leukemia 
harboring four distinct tumor clones at time of diagnosis, to 
evaluate the presence of these clonal fluctuations and to study 
clonal phyologeny in greater detail. Xenograft tumor DNA was 
analyzed using whole-exome sequencing and was compared to 
tumor exomes from the patient samples at time of diagnosis and 
first relapse. Using this strategy, Melchor et al. (2014) wanted to 
analyze whether the different clonal types would compete with 
each other and would respond differently to the given treatment. 
Interestingly, they were able to demonstrate that different clones 
exhibit distinct survival and proliferating strategies following 
patient treatment or xenotransplantation and that early clones 
that were present at nearly undetectable levels at diagnosis were 
able to survive treatment and contribute to patient relapse. These 
important observations could also be partly confirmed in the 
xenograft model, thus solidifying the observed clonal fluctuations 
and the interclonal differences in withstanding selective pressure 
under the form of treatment or xenotransplantation.
Another prime example of using murine models to study 
clonal architecture in MM was provided by Hewett et al. (2017). 
They used the 5TMM model to study the efficiency of plasma 
cell migration toward, and the capability to grow, within the 
bone marrow niche. They tagged 5TGM1 cells via transfection 
of degenerate DNA barcodes after which the cells were injected 
into C57BL/KaLwRij mice. They were able to show that MM 
cells displayed important differences in growth capabilities and 
that clones that are few in numbers can eventually give rise to 
the bulk of the disease burden. This observation suggests that 
many MM cells remain dormant and that those that migrate 
to the bone marrow are subjected to an important selection 
pressure when they interact with the bone marrow niche, as 
this observation was not seen in vitro. This concept of in vivo 
clonal competition could also be seen in the Vk*Myc mouse 
model (Keats et al., 2012). Aged Vk*MYC mice were identified 
that developed bi- or triclonal MM disease, which showed 
dynamic changes in clonal distribution without specific 
therapeutic intervention. Subsequent transplantation of bone 
marrow cells from Vk*MYC mice with biclonal M-spikes into 
congenic C57BL/6 wild-type mice showed that only one of 
both clones was able to engraft. Secondly, bone marrow cells 
from Vk*MYC mice with either an aggressive or indolent MM 
were transplanted in parallel into wild type and Vk*MYC mice 
with pre-existing MM disease, which was distinct from the 
graft. Using this approach, Keats et al. were able to show that 
the most aggressive Vk*MYC clones engrafted more rapidly in 
congenic wild type mice, were also able to engraft in Vk*MYC 
tumor bearing mice, and were able to completely replace the 
pre-existing MM clone. As indolent MM cells were not able to 
engraft in mice with pre-existing MM and took longer to engraft 
in wild-type mice, these experiments validated the concept of 
clonal variation and possible dominance. Selective pressure on 
subclones through therapeutic intervention could also be seen 
in this murine model as treatment with novel agents leads to the 
selection and progression of refractory clones.
CONCLUSION
Even in the era of novel drugs, certain MM subclones remain 
resistant to therapeutic interventions and will lead to relapse. 
Our current understanding of MM has evolved enormously and 
novel concepts, such as the involvement of genomic instability 
and its influence on drug resistance and clonal selection, leading 
to dismal patient outcomes have become very important in the 
field. As such, translational research focusing on the further 
elucidation of these aspects of MM is of the utmost importance, 
as novel insights could lead to novel treatment modalities and 
thus improve both the quantity and quality of the lives of MM 
patients. As summarized in this review, murine models are one 
of the most valuable tools to validate experimental findings in 
vivo. Luckily, many different models are present that mimic 
human disease reliably. There is, however, an important remark 
that has to be kept in mind when using murine models in MM 
research, being the fact that the different models have a different 
mode of construction, as has been described in the first part of 
this review. As such, one has to select the type of murine model 
that is best suited for the specific aspect of MM pathophysiology 
that is being studied. Also, detailed genetic characterization of 
the MM component is not present for all models and needs 
to be taken into account in view of the research question at 
hand. As such, thorough genetic analysis of the transgenic MM 
models would generate valuable additional insights into the 
pathophysiology of these widely used models, broadening our 
view on the mechanisms by which the murine MM models mimic 
human disease. Moreover, generation of additional transgenic 
MM murine models containing mutations of other specific MM 
subtypes, such as t(4;14)/MMSET, del(17p)/p53, or t(11;14)/
CCND1, would be of great interest. Concerning the xenograft 
models, recent data covering the genetic characterization 
of human MM cell lines have been published, showing that 
specific MM cell lines do indeed exhibit deregulation of 
key pathways including DNA damage response and repair 
pathways, making them interesting tools to study DNA repair 
or genomic instability and as such validate potential therapeutic 
agents (Tessoulin et al., 2018; Vikova et al., 2019). Despite these 
observations, the use of murine models remains of the utmost 
importance if we are willing to advance the field as they generate 
novel mechanistic insights into genomic instability. Using 
murine models also facilitates the identification of potential 
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therapeutic targets, such as those involved in drug resistance 
or high-risk disease. Many of these targets, exemplified in this 
review by mIR-137 and TRIP13, are, however, not fully studied 
in primary human MM samples. Additional research on the 
correlation between murine and human data, pertaining to 
disease risk characteristics or potential therapeutic responses, 
is therefore needed to be able to successfully translate murine in 
vivo findings into clinical practice. As also shown in the second 
part of this review, pre-clinical evaluation of experimental 
treatment strategies or toxicity and efficacy of novel compounds 
can only be performed in vivo and is needed to decide whether 
a promising compound can be withheld for evaluation in a 
first-in-human clinical trial. Moreover, aspects such as clonal 
evolution can only be understood to the fullest when using 
murine models.
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